We know you want to quit tobacco, and what you’re going through.There is no nagging or lecturing. We want you feel confident about quitting for good. There are so many different ways to quit.
- Tips on what to do when you have the urge to smoke or chew.
- Times and situations when you usually smoke or chew, and ways to change these routines when you quit.
- If you’ve tried to quit, we’ll talk about what hasn’t worked and new things you could try.
- We’ll tell you about medications that can help you quit. We may be able to tell you how to get free nicotine patches or gum.(Working on this hard)
A Saliva test that could be a guide in smoking cessation treatment.
A simple saliva test to assess a smoker’s degree of nicotine dependence could become the first step of a smoking
cessation treatment, a study has shown.
Light or heavy nicotine dependence can predict a person’s success in quitting or risk of relapse, Caryn Lerman, Ph.D., said at the annual meeting of the Society of Behavioral Medicine. Clinicians could use this information to guide treatment choices for their patients.
“We could decide whether someone needs smoking cessation counseling only, or whether they would do better with a patch, or if they need a medication such as bupropion or varenicline,” said Dr. Lerman of the Transdisciplinary Tobacco Use Research Center at the University of Pennsylvania, Philadelphia.
The saliva test measures the ratio of two nicotine metabolites, 3′-hydroxycotinine and co-tinine, to determine a person’s rate of nicotine clearance or metabolism, Dr. Lerman said.
A new study by her group has validated that smokers with the slowest nicotine metabolism are about twice as likely to quit as are smokers with faster nicotine metabolism. The study enrolled 568 smokers who were given counseling and 8 weeks of a 21-mg nicotine patch. The saliva test measured the metabolite ratio pretreatment to distinguish fast from slow nicotine metabolizers. Eight weeks after the quit date, fast metabolizers were approximately 50% less likely to be abstinent, compared with slow metabolizers (28% vs. 42%).
The findings support the value of the saliva test as a bio-marker to predict success with transdermal nicotine for smoking cessation, the authors concluded. “We are developing a treatment algorithm which suggests that slow metabolizers may need nothing more than counseling or nicotine patch, but fast metabolizers are candidates for more nonnicotine medications which may be more costly and have more side effects than the patch.